SCHEMBL10123650

SCHEMBL10123650

CC(=O)c1ccn2ccc(C#N)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
PGR P06401 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
PGGT1B P53609 1/20 0.35
ALDH1A1 P00352 4/20 0.35
NOTUM Q6P988 1/20 0.35
MAPT P10636 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
APAF1 O14727 1/20 0.34
RAB9A P51151 2/20 0.33
GALR3 O60755 1/20 0.33
NPC1 O15118 1/20 0.33
IMPDH2 P12268 2/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343524 0.85 ALDH1A1 (0.38) ALDH1A1
SCHEMBL343474 0.79 CA12 (0.44) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL10123575 0.73 MAOA (0.35) KMT2AALDH1A1IMPDH2KDM4E
SCHEMBL10123651 0.71 CDC7 (0.33) ALDH1A1IMPDH2KDM4E
SCHEMBL10123635 0.70 GABRA1 (0.37) CYP11B2PGR
SCHEMBL10123639 0.69 KIF11 (0.35) PGRFNTAFNTBPGGT1BALDH1A1
SCHEMBL10123632 0.69 ALDH1A1 (0.34) MEN1KMT2APGRALDH1A1L3MBTL1
SCHEMBL10123594 0.69 CYP2A6 (0.38) ALDH1A1MAPTRAB9ANPC1CTSS
SCHEMBL344208 0.69 KDM4E (0.43) MEN1KMT2APGRALDH1A1MAPT
SCHEMBL343188 0.69 CSNK2A1 (0.34) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 MEN1 2393/4885KMT2A 2454/4885CYP11B1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.